CellTrans

CellTrans is a private, clinical-stage biotech focused on functional cures through cell transplantation, most notably with its FDA-approved therapy LANTIDRA for Type 1 diabetes. The company operates a dual business model, combining its own therapeutic development with a fee-for-service arm offering pre-clinical, clinical, and in-vitro testing services for external clients. Led by a founder with deep clinical transplant expertise and supported by a seasoned operational team, CellTrans leverages its cGMP manufacturing and quality systems to advance its pipeline and support partners in the cell and gene therapy space.

Proprietary cGMP platform for the isolation, characterization, and manufacturing of human pancreatic islet cells for transplantation, with supporting expertise in pre-clinical testing and in-vitro cell product assessment.

In diabetes cell therapy, CellTrans's LANTIDRA is the first approved allogeneic islet product, competing with other investigational approaches from companies like Vertex (VX-880/VX-264) and Sernova. In the service/CDMO space, it competes with larger, broad-service CDMOs but differentiates through deep, niche expertise in islet and complex cell processing.